Clementine Feau
St. Jude Children's Research Hospital
9 Papers
11 Citations
Clementine Feau is an academic researcher from St. Jude Children's Research Hospital. The author has contributed to research in topics: Androgen receptor & Receptor. The author has an hindex of 7, co-authored 9 publications.
Chat about Author
Papers
An integrated in vitro and in vivo high throughput screen identifies treatment leads for ependymoma
Jennifer M. Atkinson,Anang A. Shelat,Angel M. Carcaboso,Tanya A. Kranenburg,Leggy A. Arnold,Nidal Boulos,Karen Wright,Robert A. Johnson,Helen Poppleton,Kumarasamypet M. Mohankumar,Clementine Feau,Timothy N. Phoenix,Paul Gibson,Liqin Zhu,Yiai Tong,Christopher J. Eden,David W. Ellison,Waldemar Priebe,Dimpy Koul,W. K. Alfred Yung,Amar Gajjar,Clinton F. Stewart,R. Kiplin Guy,Richard J. Gilbertson +23 more
TL;DR: This comprehensive approach advances understanding of the biology and treatment of ependymoma including the discovery of several treatment leads for immediate clinical translation.
109
Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents
Jaeki Min,Kexiao Guo,Praveen Kumar Suryadevara,Fangyi Zhu,Gloria Holbrook,Yizhe Chen,Clementine Feau,Brandon Young,Andrew Lemoff,Michele Connelly,Michael B. Kastan,R. Kiplin Guy +11 more
TL;DR: It is shown that, while the C-7-methoxy group is essential for potency, replacing theC-6-mETHoxy group considerably improves metabolic stability without affecting potency, and 27g is a good candidate for further development as a potential radiosensitizer.
41
A high-throughput ligand competition binding assay for the androgen receptor and other nuclear receptors.
TL;DR: The authors describe a radiolabeled ligand competition scintillation proximity assay (SPA) for the androgen receptor (AR) using Ni-coated 384-well FlashPlates® and liganded AR-LBD protein that is well suited for automated high-throughput screening.
28
Ligand Competition Binding Assay for the Androgen Receptor
TL;DR: This work has utilized a radiolabeled ligand competition binding assay for the androgen receptor (AR) that can be carried out in a 384-well format and has been automated for high-throughput screening (HTS) purposes.
6